[go: up one dir, main page]

WO2019118314A3 - Scintillation proximity assay system comprising mutant dehalogenase - Google Patents

Scintillation proximity assay system comprising mutant dehalogenase Download PDF

Info

Publication number
WO2019118314A3
WO2019118314A3 PCT/US2018/064650 US2018064650W WO2019118314A3 WO 2019118314 A3 WO2019118314 A3 WO 2019118314A3 US 2018064650 W US2018064650 W US 2018064650W WO 2019118314 A3 WO2019118314 A3 WO 2019118314A3
Authority
WO
WIPO (PCT)
Prior art keywords
scintillation proximity
assay system
proximity assay
mutant dehalogenase
dehalogenase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/064650
Other languages
French (fr)
Other versions
WO2019118314A2 (en
Inventor
Scott E. Wolkenberg
Raphaelle BERGER
Paul Tawa
Keith P. Moore
Xiaoqing Han
Marla L. WATT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon Pharma UK Ltd
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme Ltd
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme Ltd, Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme Ltd
Publication of WO2019118314A2 publication Critical patent/WO2019118314A2/en
Publication of WO2019118314A3 publication Critical patent/WO2019118314A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

The present invention provides an assay system comprising a novel combination of Scintillation proximity assay (SPA) technology and a CaptureProtein/Capture Ligand system and methods for its use.
PCT/US2018/064650 2017-12-13 2018-12-10 Scintillation proximity assay system comprising mutant dehalogenase Ceased WO2019118314A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762598079P 2017-12-13 2017-12-13
US62/598,079 2017-12-13

Publications (2)

Publication Number Publication Date
WO2019118314A2 WO2019118314A2 (en) 2019-06-20
WO2019118314A3 true WO2019118314A3 (en) 2020-03-26

Family

ID=66819476

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/064650 Ceased WO2019118314A2 (en) 2017-12-13 2018-12-10 Scintillation proximity assay system comprising mutant dehalogenase

Country Status (1)

Country Link
WO (1) WO2019118314A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023225369A1 (en) * 2022-05-19 2023-11-23 Duke University Compounds, compositions, and methods for cell-specific pharmacology

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5815262A (en) * 1995-09-07 1998-09-29 Basf Aktiengesellschaft Apparatus for parallelized two-photon fluorescence correlation spectroscopy (TPA-FCS), and the use thereof for screening active compounds
US20050221381A1 (en) * 2002-02-28 2005-10-06 Christof Klade Method for isolating ligands
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US20100120171A1 (en) * 2006-11-23 2010-05-13 Isabelle Vilgrain Circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment and improved method for the detection of soluble proteins
CN104530415A (en) * 2014-10-01 2015-04-22 厦门赛诺邦格生物科技有限公司 Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof
WO2016090157A1 (en) * 2014-12-04 2016-06-09 Celgene Corporation Biomolecule conjugates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5815262A (en) * 1995-09-07 1998-09-29 Basf Aktiengesellschaft Apparatus for parallelized two-photon fluorescence correlation spectroscopy (TPA-FCS), and the use thereof for screening active compounds
US20050221381A1 (en) * 2002-02-28 2005-10-06 Christof Klade Method for isolating ligands
US7429472B2 (en) * 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
US20100120171A1 (en) * 2006-11-23 2010-05-13 Isabelle Vilgrain Circulating ve-cadherin as a predictive marker of sensitivity or resistance to anti-tumoral treatment and improved method for the detection of soluble proteins
CN104530415A (en) * 2014-10-01 2015-04-22 厦门赛诺邦格生物科技有限公司 Hetero-functionalized Y-type polyethylene glycol derivative, preparation method and biologically related substance thereof
WO2016090157A1 (en) * 2014-12-04 2016-06-09 Celgene Corporation Biomolecule conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MCREYNOLDS ET AL.: "Synthesis of Hydrophilic Aminooxy Linkers and Multivalent Cores for Chemoselective Aldehyde/Ketone Conjugation", TETRAHEDRON LETTERS, vol. 55, no. 14, 2 April 2014 (2014-04-02), pages 2270 - 2273, XP028835491, DOI: 10.1016/j.tetlet.2014.02.085 *
UCHIYAMA ET AL.: "Role of Heterotrophic Bacteria in Complete Mineralization of Trichloroethylene by Methylocystis sp. Strain M", APPLIED AND ENVIRONMENTAL MICROBIOLOGY, vol. 58, no. 9, September 1992 (1992-09-01), pages 3067 - 3071, XP055694618 *

Also Published As

Publication number Publication date
WO2019118314A2 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
AU2017240185A1 (en) Photosensitive dispersion and use thereof
MX2017006094A (en) Anti-interleukin-33 antibodies and uses thereof.
BR112017008666A2 (en) anti-fgfr2 / 3 antibodies and methods of use
PH12017500877B1 (en) ANTI-CD79b ANTIBODIES AND METHODS OF USE
MY193661A (en) Anti-tim3 antibodies and methods of use
SG10201808259TA (en) Anti-jagged1 antibodies and methods of use
MX2020010379A (en) Systems and methods for processing.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2021002616A (en) Anti-trem-2 agonist antibodies.
EP4015531A3 (en) Mutant pore
WO2018081648A8 (en) Anti-mic antibodies and methods of use
SG10201804931QA (en) Anti-cll-1 antibodies and immunoconjugates
EP4465050A3 (en) Anti-tau antibodies and methods of use
MX2019006334A (en) Anti-tau antibodies and methods of use.
WO2018048867A8 (en) Systems and methods for actuating hydraulically-actuated devices
MY178578A (en) Medical pendant arm system and rotation shaft used for the same
GB2547567A (en) Contractile function measuring devices, systems, and methods of use thereof
TWD173728S (en) Display stand
PH12020551336A1 (en) Anti-klk5 antibodies and methods of use
MX2020004241A (en) Connector and connector assembly.
WO2018046997A3 (en) Synthetic antibodies against vegf and their uses
MX2023006458A (en) IMMUNOMODULATORY OLIGOSACCHARIDES.
WO2019194875A3 (en) Oxidase-based sensors and methods of using
MX2017001397A (en) Control terminal for processing systems.
EP3340209A4 (en) Housing and system

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18887720

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18887720

Country of ref document: EP

Kind code of ref document: A2